The global battle against SARS-CoV-2 and COVID-19 at the third year.
作者信息
Deng Chu-Xia
机构信息
Editor in Chief, International Journal of Biological Sciences.
Chair Professor, Faculty of Health Sciences, University of Macau.
出版信息
Int J Biol Sci. 2022 Jul 13;18(12):4792-4794. doi: 10.7150/ijbs.76035. eCollection 2022.
Abstract
摘要
相似文献
1
The global battle against SARS-CoV-2 and COVID-19 at the third year.抗击严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和新型冠状病毒肺炎（COVID-19）的全球战斗进入第三年。
Int J Biol Sci. 2022 Jul 13;18(12):4792-4794. doi: 10.7150/ijbs.76035. eCollection 2022.
2
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.SARS-CoV-2 反应性 T 细胞在健康供体和 COVID-19 患者中的研究。
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
3
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
4
Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein.人 Basigin（CD147）与 SARS-CoV-2 刺突糖蛋白不直接相互作用。
mSphere. 2021 Aug 25;6(4):e0064721. doi: 10.1128/mSphere.00647-21. Epub 2021 Aug 11.
5
CD4 T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein.前列腺癌患者的 CD4 T 细胞对源自 SARS-CoV-2 刺突糖蛋白的抗原的免疫反应降低。
Front Immunol. 2021 May 3;12:629102. doi: 10.3389/fimmu.2021.629102. eCollection 2021.
6
Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.SARS-COV-2 刺突糖蛋白的优化假型条件。
J Virol. 2020 Oct 14;94(21). doi: 10.1128/JVI.01062-20.
7
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
8
Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.用于检测 COVID-19 恢复期血浆中 SARS-CoV-2 特异性 IgG 的多重冠状病毒抗原阵列的评估。
J Immunol Methods. 2021 Oct;497:113104. doi: 10.1016/j.jim.2021.113104. Epub 2021 Jul 22.
9
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.CD147-刺突蛋白是 SARS-CoV-2 感染宿主细胞的新途径。
Signal Transduct Target Ther. 2020 Dec 4;5(1):283. doi: 10.1038/s41392-020-00426-x.
10
Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.探索刺突蛋白作为新型冠状病毒的潜在靶点，并利用天然药物抑制其活性。
Curr Drug Targets. 2021;22(17):2006-2020. doi: 10.2174/1389450122666210309105820.
引用本文的文献
1
Post COVID-19 vaccination binding and neutralizing antibody with or without previous infection: An 18-month longitudinal study in Indonesia.新冠病毒疫苗接种后有无既往感染情况下的结合抗体和中和抗体：印度尼西亚一项为期18个月的纵向研究
Narra J. 2024 Aug;4(2):e1071. doi: 10.52225/narra.v4i2.1071. Epub 2024 Aug 31.
本文引用的文献
1
The continued global battle against SARS-CoV-2 and COVID-19.全球针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和冠状病毒病（COVID-19）的持续战斗。
Int J Biol Sci. 2021 Apr 10;17(6):1440-1442. doi: 10.7150/ijbs.60639. eCollection 2021.
2
COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.COVID-19 与非酒精性脂肪性肝病：两大流行病的交集。
Eur J Clin Invest. 2020 Oct;50(10):e13338. doi: 10.1111/eci.13338. Epub 2020 Aug 26.
3
Exportin 1 inhibition as antiviral therapy.Exportin 1 抑制作为抗病毒疗法。
Drug Discov Today. 2020 Oct;25(10):1775-1781. doi: 10.1016/j.drudis.2020.06.014. Epub 2020 Jun 20.
4
The global battle against SARS-CoV-2 and COVID-19.全球抗击严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和冠状病毒病（COVID-19）之战。
Int J Biol Sci. 2020 Mar 15;16(10):1676-1677. doi: 10.7150/ijbs.45587. eCollection 2020.
5
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
Zotero 插件